131 related articles for article (PubMed ID: 1846868)
1. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin.
Mortola JF; Girton L; Fischer U
J Clin Endocrinol Metab; 1991 Feb; 72(2):252A-252F. PubMed ID: 1846868
[TBL] [Abstract][Full Text] [Related]
2. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome.
Mezrow G; Shoupe D; Spicer D; Lobo R; Leung B; Pike M
Fertil Steril; 1994 Nov; 62(5):932-7. PubMed ID: 7926137
[TBL] [Abstract][Full Text] [Related]
3. Applications of gonadotropin-releasing hormone analogues in the treatment of premenstrual syndrome.
Mortola JF
Clin Obstet Gynecol; 1993 Sep; 36(3):753-63. PubMed ID: 8403622
[TBL] [Abstract][Full Text] [Related]
4. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
5. Premenstrual syndrome.
DeVane GW
J Clin Endocrinol Metab; 1991 Feb; 72(2):250-1. PubMed ID: 1846867
[No Abstract] [Full Text] [Related]
6. Effects of estrogen with and without progestin on urinary incontinence.
Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
[TBL] [Abstract][Full Text] [Related]
7. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
Pickar JH; Yeh IT; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2003 Nov; 80(5):1234-40. PubMed ID: 14607581
[TBL] [Abstract][Full Text] [Related]
8. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Pickar JH; Yeh I; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2001 Jul; 76(1):25-31. PubMed ID: 11438315
[TBL] [Abstract][Full Text] [Related]
9. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate.
Cedars MI; Lu JK; Meldrum DR; Judd HL
Obstet Gynecol; 1990 Apr; 75(4):641-5. PubMed ID: 2138265
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study.
Harden CL; Herzog AG; Nikolov BG; Koppel BS; Christos PJ; Fowler K; Labar DR; Hauser WA
Epilepsia; 2006 Sep; 47(9):1447-51. PubMed ID: 16981859
[TBL] [Abstract][Full Text] [Related]
11. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
[TBL] [Abstract][Full Text] [Related]
12. Anti-ischemic effect of chronic oestrogen replacement therapy alone or in combination with medroxyprogesterone acetate in different replacement schemes.
Cerquetani E; Leonardo F; Pagnotta P; Galetta P; Onorati D; Fini M; Rosano GM
Maturitas; 2001 Sep; 39(3):245-51. PubMed ID: 11574184
[TBL] [Abstract][Full Text] [Related]
13. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
Berga SL; Yen SS
Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
[TBL] [Abstract][Full Text] [Related]
14. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Utian WH; Shoupe D; Bachmann G; Pinkerton JV; Pickar JH
Fertil Steril; 2001 Jun; 75(6):1065-79. PubMed ID: 11384629
[TBL] [Abstract][Full Text] [Related]
15. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
[TBL] [Abstract][Full Text] [Related]
16. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.
Barrett-Connor E; Slone S; Greendale G; Kritz-Silverstein D; Espeland M; Johnson SR; Waclawiw M; Fineberg SE
Maturitas; 1997 Jul; 27(3):261-74. PubMed ID: 9288699
[TBL] [Abstract][Full Text] [Related]
17. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism.
Lobo RA; Bush T; Carr BR; Pickar JH
Fertil Steril; 2001 Jul; 76(1):13-24. PubMed ID: 11438314
[TBL] [Abstract][Full Text] [Related]
18. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy.
Kirkham C; Hahn PM; Van Vugt DA; Carmichael JA; Reid RL
Obstet Gynecol; 1991 Jul; 78(1):93-7. PubMed ID: 1828550
[TBL] [Abstract][Full Text] [Related]
20. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen.
Sundström I; Nyberg S; Bixo M; Hammarbäck S; Bäckström T
Acta Obstet Gynecol Scand; 1999 Nov; 78(10):891-9. PubMed ID: 10577620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
